Welcome to Awesome Blog Design perfect blog
Healthcare, News Now!

Covid-19 News: Live Updates

U.S. colleges are cracking down on parties as campus infections rise. South Korea’s much vaunted strategy for battling the virus is under pressure as a second wave of cases sweeps the country.

Healthcare

Legend Biotech reports second quarter 2020 financial results

SOMERSET, N.J.–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported financial results for the quarter ended June 30, 2020. “Legend Biotech

Business, Healthcare

Topcon announces the U.S. launch of Aladdin-M

Company Introduces Tool for Measuring and Monitoring Axial Length Metrics OAKLAND, N.J.–(BUSINESS WIRE)–#SeeingEyeHealthDifferently–Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it has launched its new Aladdin-M instrument to the US

Healthcare

Merck’s KEYTRUDA® (pembrolizumab) receives two new approvals in Japan

KEYTRUDA Now Approved for Patients With PD-L1-Positive Esophageal Squamous Cell Carcinoma Who Have Progressed After Chemotherapy and for a Six-Week Dosing Schedule Across All Adult Indications Six-Week Dosing Schedule for KEYTRUDA Now Approved in Japan, US and Europe KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck

Business, Healthcare

Eagle Pharmaceuticals announces publication of preclinical study of Intranasal Dantrolene in Journal of Alzheimer’s Disease

WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that preclinical research on dantrolene sodium was published today in the peer-reviewed Journal of Alzheimer’s Disease.1 The article reported results from an academic-based study that demonstrated dantrolene sodium

Business, Healthcare

Merck’s KEYTRUDA® (pembrolizumab) in combination with chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in locally advanced or first-line metastatic esophageal cancer

KEYTRUDA Is First Anti-PD-1 Therapy in Combination With Chemotherapy to Show Superior Survival Benefit as First-Line Treatment for Patients With Esophageal Cancer Regardless of Histology Results of Phase 3 KEYNOTE-590 Trial to be Submitted to Global Regulatory Authorities KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck